BioCentury
ARTICLE | Cover Story

mAbs that live long and prosper

January 21, 2010 8:00 AM UTC

Independent teams at The University of Texas at Austinand Xencor Inc.have come up with strategies to improve the effectiveness and durability of cancer mAbs. Both approaches involve modifying the invariant region common to all mAbs to increase their binding to receptors on innate immune cells and endothelial cells.

The biotech is using its strategy to develop an extended half-life mAb and has licensed the technology to several pharma companies...